MBX Biosciences (MBX) Q1 2026 earnings summary

Executive summary

• Advancing novel precision peptide therapies for endocrine and metabolic disorders, with lead candidates canvuparatide, MBX 4291, and imapextide progressing through clinical stages.

• Completed End of Phase 2 FDA meeting for canvuparatide; Phase 3 trial initiation planned for Q3 2026.

• MBX 4291 Phase 1 trial ongoing, with 12-week MAD results expected in Q4 2026; imapextide Phase 2a topline results expected Q2 2026.

• No approved products or product revenue; operations funded by equity and public offerings.

• Appointment of new Chief Commercial Officer to strengthen commercialization capabilities.

Financial highlights

• Net loss of $23.5 million for Q1 2026, compared to $23.9 million in Q1 2025.

• R&D expenses decreased to $18.5 million from $22.4 million year-over-year, mainly due to timing of clinical activities.

• G&A expenses increased to $8.8 million from $4.1 million, driven by higher personnel costs and infrastructure expansion.

• Cash, cash equivalents, and marketable securities totaled $440.0 million as of March 31, 2026, expected to fund operations into 2029.

• Interest and other income rose to $3.7 million from $2.6 million, reflecting higher cash balances from recent offerings.

Outlook and guidance

• Existing cash and marketable securities expected to fund operations into 2029.

• Phase 3 canvuparatide trial initiation expected in Q3 2026; key clinical data for pipeline candidates anticipated in 2026.

• Nomination of new obesity candidates, including an amycretin prodrug in Q2 2026 and a GLP-1/GIP/GCGR triple-agonist prodrug in Q3 2026.

• Oral presentation of Phase 2 Avail™ and one-year OLE data scheduled for Q2 2026.

• Anticipates increased expenses as clinical programs advance and company transitions toward commercialization.